Correlation Between DexCom and CG Oncology,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both DexCom and CG Oncology, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DexCom and CG Oncology, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between DexCom Inc and CG Oncology, Common, you can compare the effects of market volatilities on DexCom and CG Oncology, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DexCom with a short position of CG Oncology,. Check out your portfolio center. Please also check ongoing floating volatility patterns of DexCom and CG Oncology,.

Diversification Opportunities for DexCom and CG Oncology,

-0.55
  Correlation Coefficient

Excellent diversification

The 3 months correlation between DexCom and CGON is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding DexCom Inc and CG Oncology, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CG Oncology, Common and DexCom is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DexCom Inc are associated (or correlated) with CG Oncology,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CG Oncology, Common has no effect on the direction of DexCom i.e., DexCom and CG Oncology, go up and down completely randomly.

Pair Corralation between DexCom and CG Oncology,

Given the investment horizon of 90 days DexCom Inc is expected to generate 0.78 times more return on investment than CG Oncology,. However, DexCom Inc is 1.29 times less risky than CG Oncology,. It trades about 0.22 of its potential returns per unit of risk. CG Oncology, Common is currently generating about -0.02 per unit of risk. If you would invest  7,048  in DexCom Inc on September 1, 2024 and sell it today you would earn a total of  751.00  from holding DexCom Inc or generate 10.66% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy95.45%
ValuesDaily Returns

DexCom Inc  vs.  CG Oncology, Common

 Performance 
       Timeline  
DexCom Inc 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in DexCom Inc are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, DexCom may actually be approaching a critical reversion point that can send shares even higher in December 2024.
CG Oncology, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days CG Oncology, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, CG Oncology, is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

DexCom and CG Oncology, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with DexCom and CG Oncology,

The main advantage of trading using opposite DexCom and CG Oncology, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DexCom position performs unexpectedly, CG Oncology, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology, will offset losses from the drop in CG Oncology,'s long position.
The idea behind DexCom Inc and CG Oncology, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon